RVTY REVVITY, INC.
Price Chart
Executive Summary
Revvity reported Q1 2026 adjusted EPS of $1.06, beating the $1.02 consensus by 3.9%, on reported revenue of $711M (7% YoY growth, 3% organic). The company announced plans to divest its China Immunodiagnostics business (6% of 2025 revenue) for up to $200M and updated FY2026 pro forma guidance to $2.81-$2.84B revenue and $5.20-$5.30 adjusted EPS. While the quarter was solid, the divestiture introduces execution risk and the guidance implies a deceleration from Q1's pace, making the overall read-through mixed.
Key Financial Metrics
Actionable Insight
The Q1 beat was modest and margins compressed, but the real story is the China IDX divestiture — a strategic portfolio simplification that removes ~6% of revenue but could improve margins. The pro forma guidance implies H2 deceleration from Q1's 6% pro forma organic growth to ~3-4% for the full year. Watch for definitive agreement details in Q2 and whether proceeds are used for debt reduction or further buybacks. The stock may trade range-bound until the divestiture closes in 2027.
Key Facts
- Q1 2026 GAAP EPS from continuing operations: $0.37 (vs $0.35 YoY); adjusted EPS: $1.06 (vs $1.01 YoY)
- Q1 2026 reported revenue: $711M (7% YoY growth); organic revenue growth: 3%; pro forma organic growth: 6%
- Announced intention to divest China Immunodiagnostics business (~6% of FY2025 revenue) for up to $200M; LOI signed April 16, 2026; definitive agreement expected Q2 2026; close expected 2027
- Updated FY2026 pro forma guidance: revenue $2.81-$2.84B, pro forma organic growth 3%-4%, pro forma adjusted EPS $5.20-$5.30
- Prior FY2026 guidance (Feb 2026) was $2.96-$2.99B revenue and adjusted EPS $5.35-$5.45 on a reported basis; the new pro forma guidance excludes the China IDX business
- Life Sciences segment revenue: $362M (+6% YoY); Diagnostics: $349M (+8% YoY)
- Adjusted operating margin contracted to 23.6% from 25.6% YoY; GAAP operating margin was 10.7% vs 10.9%
- Operating cash flow from continuing operations: $125.9M vs $134.1M YoY; share repurchases of $86.5M in Q1
Financial Impact
Divestiture of China IDX for up to $200M; business represented ~$171M of FY2025 revenue (6% of total). Pro forma guidance implies FY2026 revenue of $2.81-$2.84B, down from prior $2.96-$2.99B reported guidance due to the exclusion.
Risk Factors
- Divestiture execution risk — definitive agreement not yet signed; regulatory approvals in China could delay or derail the deal
- Pro forma guidance implies slowing organic growth in H2 2026 vs Q1's 6% pro forma pace
- Adjusted operating margin declining YoY (23.6% vs 25.6%) — cost pressures or mix shift
- Operating cash flow declined 6% YoY to $125.9M
- Restructuring charges of $10.7M in Q1 suggest ongoing cost-cutting
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000031791-26-000016 |
| Document: q12026proformafinancialsta.htm | 0000031791-26-000016 |
| Document: pki-20260505.htm | 0000031791-26-000016 |
| Document: 0000031791-26-000016-index-headers.html | 0000031791-26-000016 |
| Document: 0000031791-26-000016-index.html | 0000031791-26-000016 |
| Document: 0000031791-26-000016.txt | 0000031791-26-000016 |
| 8-K Data (Synthetic) | 0000031791-26-000016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 5, 2026
5w ago
|
8-K
| $92.30 $100.39 | ▲ +8.76% | ▲ +3.81% | $99.66 (+7.97%) |
|
Mar 16, 2026
12w ago
|
DEFA14A
| $86.41 $93.44 | ▲ +8.13% | ▲ +4.35% | $99.66 (+15.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access